Predict your next investment

Hedge Fund
granitepoint.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

2

About Granite Point Capital

Granite Point Capital Headquarter Location

222 Berkeley Street

Boston, Massachusetts, 02116,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Granite Point Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Granite Point Capital in 1 CB Insights research brief, most recently on Jul 19, 2021.

Latest Granite Point Capital News

Antios Therapeutics Raises $96 Million in a Series B Financing

Apr 29, 2021

By Antios Therapeutics, Inc. on Monday, Apr 12, 2021 Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and Life Sci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital MENDHAM, N.J., April 12, 2021 (GLOBE NEWSWIRE) – Antios Therapeutics, Inc. (“Antios”) today announced the successful completion of a $96 million Series B financing. The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B. ATI-2173 is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) that can shut down HBV polymerase activity and viral replication. The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital. David Canner, Partner at Soleus Capital and Iyona Rajkomar, MBBS, CFA, Partner at Pontifax, are joining the Board of Directors. “ATI-2173 has already demonstrated potent on-treatment and durable off-treatment effects in our Phase 1b study in patients with chronic hepatitis B,” said Greg Mayes, Chief Executive Officer of Antios. “Those results will be presented at an upcoming major medical conference. With this financing we are now well positioned to continue to highlight how ATI-2173 may become the backbone of a curative regimen for HBV which remains a significant unmet global public health need. We look forward to working with new and existing investors to advance ATI-2173 forward in development.” Guy Levy, Chief Investment Officer of Soleus Capital said, “Despite significant progress in recent years, HBV remains an area of high unmet medical need. Given the mechanistic rationale and impressive early data, we believe ATI-2173 could play an essential role in developing curative regimens for the millions of people suffering from chronic HBV infection. We are excited to partner with the experienced team at Antios to help bring this therapy to patients.” About ATI-2173 ATI-2173 is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) molecule designed to deliver the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s active 5’-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site of HBV polymerase resulting in potent HBV antiviral activity and extended off-treatment suppression of HBV DNA. ATI-2173 targets the liver, delivering high levels of the unique 5’- triphosphate while limiting systemic exposure to the parent L-nucleoside. ATI-2173 has the potential to become an integral part of a curative combination regimen for chronic hepatitis B. About Antios Therapeutics Inc. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen. Copyright © Antios Therapeutics. All rights reserved.

Granite Point Capital Investments

13 Investments

Granite Point Capital has made 13 investments. Their latest investment was in Teikametrics as part of their Series B - II on July 7, 2021.

CBI Logo

Granite Point Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/15/2021

Series B - II

Teikametrics

$40M

No

2

4/12/2021

Series B

Antios Therapeutics

$96M

Yes

3

2/20/2020

Series B

Teikametrics

$15M

No

7

1/7/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/20/2019

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/15/2021

4/12/2021

2/20/2020

1/7/2020

3/20/2019

Round

Series B - II

Series B

Series B

Series B

Series A - III

Company

Teikametrics

Antios Therapeutics

Teikametrics

Subscribe to see more

Subscribe to see more

Amount

$40M

$96M

$15M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

7

10

10

Granite Point Capital Portfolio Exits

2 Portfolio Exits

Granite Point Capital has 2 portfolio exits. Their latest portfolio exit was HealthGuru Media on December 04, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/4/2013

Acquired

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

12/4/2013

00/00/0000

Exit

Acquired

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Sources

1

10

Granite Point Capital Team

2 Team Members

Granite Point Capital has 2 team members, including current Founder, Chief Investment Officer, Warren Lammert.

Name

Work History

Title

Status

Warren Lammert

Founder

Current

Warren Lammert

Fred Alger Management

Founder, Chief Investment Officer

Current

Name

Warren Lammert

Warren Lammert

Work History

Fred Alger Management

Title

Founder

Founder, Chief Investment Officer

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.